Smith & Nephew Reports Strong Start to 2025 with Revenue Growth

An update from Smith & Nephew Snats ( (SNN) ) is now available.

Smith & Nephew reported a positive start to 2025 with its first-quarter revenue reaching $1,407 million, marking a 3.1% underlying growth compared to the previous year. The growth was driven by operational improvements and new product launches, despite challenges from foreign exchange rates and market conditions in China. The company maintains its full-year guidance, expecting around 5.0% underlying revenue growth and a significant increase in trading profit margins. CEO Deepak Nath highlighted strong performances from key platforms and a continued focus on innovation, although tariff uncertainties remain a concern.

Spark’s Take on SNN Stock

According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.

Smith & Nephew Snats receives a solid overall score of 77.0, driven by strong financial performance and positive earnings call sentiment. The company’s impressive revenue and profit growth, coupled with innovation-driven strategies, contribute to a favorable outlook. However, high valuation ratios and technical analysis indicators suggest caution. Challenges in the China market and input cost pressures in Orthopedics remain key risks.

To see Spark’s full report on SNN stock, click here.

More about Smith & Nephew Snats

Smith & Nephew is a global medical technology company that operates in the healthcare industry, focusing on orthopaedics, sports medicine, and advanced wound management. The company is known for its innovative products such as hip and knee implants, sports medicine joint repair technologies, and negative pressure wound therapy solutions.

YTD Price Performance: 10.79%

Average Trading Volume: 854,802

Technical Sentiment Signal: Hold

Current Market Cap: $11.72B

Learn more about SNN stock on TipRanks’ Stock Analysis page.